Less Toxic, More Targeted

With a first-in-the-world clinical trial underway, Leonid Metelitsa, MD, PhD, anticipates that a combination CAR NKT therapy will be successful against refractory pediatric neuroblastoma.

Preventing a Parasite

First clinical trial tests new vaccine